The proportion cured of patients diagnosed with Stage III–IV cutaneous malignant melanoma in <scp>S</scp>weden 1990–2007: A population‐based study

Eriksson, Hanna; Lyth, Johan; Andersson, Therése

doi:10.1002/ijc.30023

Cited by 8 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with locoregional metastases had somewhat lower risk of later developing distant metastases than men independent of age. A previous study on patients with stage III at primary diagnosis also showed heterogenic survival outcome between men and women . For patients with distant metastases, M1c (65%) was the dominating site which could be compared to AJCC data (stage IV at primary diagnosis) where the proportion of M1c was 58% …”

Section: Discussionmentioning

confidence: 84%

“…A previous study on patients with stage III at primary diagnosis also showed heterogenic survival outcome between men and women. 19 For patients with distant metastases, M1c (65%) was the dominating site which could be compared to AJCC data (stage IV at primary diagnosis) where the proportion of M1c was 58%. 3 In the present study, 37.6% of the patients with recurrences developed distant metastases without previous locoregional metastases indicating haematogenous metastases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic risk factors of first recurrence in patients with primary stages I–II cutaneous malignant melanoma – from the population‐based Swedish melanoma register

Lyth

Falk

Maroti

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Prognostic risk factors of first recurrence in patients with primary stages I–II cutaneous malignant melanoma – from the population‐based Swedish melanoma register

Lyth

Falk

Maroti

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Each risk factor (period of diagnosis, age, sex and WCC) was included in a univariable model and a fully adjusted model including all the covariates. The cure model provides estimates separately for each combination of covariates in the model, therefore to make comparisons between levels of each covariate while adjusting for the others we calculated standardised estimates (Andersson et al , ; Eriksson et al , ). For example, the cure proportion for each sex was estimated assuming that the distribution of the other covariates (age, period of diagnosis and WCC) was the same as the whole study population.…”

Section: Methodsmentioning

confidence: 99%

Long‐term survival after childhood acute lymphoblastic leukaemia: population‐based trends in cure and relapse by clinical characteristics

et al. 2018

View full text Add to dashboard Cite

'Cure models' offer additional information to traditional epidemiological approaches to assess survival for cancer patients by simultaneously estimating the proportion cured and the survival of those 'uncured'. The proportion cured is a summary of long-term survival while the median survival time of the uncured provides important information on those who are not long-term survivors. Population-based trends in the cure proportion and survival of the uncured for childhood acute lymphoblastic leukaemia (ALL) by clinical prognostic risk factors were estimated using flexible parametric cure models, based on overall survival and event-free survival. Children aged 1-17 years diagnosed between 1990 and 2011 in Yorkshire, UK, were included (n = 492). The percentage cured increased from 77% (95% confidence interval 70-84%) in 1990-1997 to 89% (84-93%) in 2003-2011, while the median survival time of the uncured decreased from 3·2 years (2·2-4·1 years) to 0·7 years (0-1·5 years). Models based on event-free survival showed a similar trend. The 5-year cumulative incidence of relapse substantially decreased from 35% in 1990-97 to 9% in 2003-2011. These results show selective improvement in survival between 1990 and 2011 with a significant reduction in the risk of relapse alongside a reduced absolute duration of survival for those destined to be uncured.

show abstract

“…In Sweden it is the fifth most prevalent malignant neoplasm both in men (following prostate, colon, non-melanocytic skin and urinary tract tumors) and women (following breast, colon, non-melanocytic skin and uterine neoplasms) with an annual incidence of 5% [3, 4]. …”

Section: Introductionmentioning

confidence: 99%

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

et al. 2017

View full text Add to dashboard Cite

BackgroundMetastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a versatile approach with high throughput data and results that can be used for characterizing tissue samples. However, such analysis is hampered by the complexity of the disease, heterogeneity of patients, tumors, and samples themselves. With the long term aim of quest for better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on relating high resolution proteomics data to careful histopathological evaluation of the tumor samples and patient survival information.Patients and methodsRegional lymph node metastases obtained from ten patients with metastatic melanoma (stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrometry data was related to the histopathology tumor tissue sections adjacent to the area used for deep-mining. Clinical follow-up data provided information on disease progression which could be linked to protein expression aiming to identify tissue-based specific protein markers for metastatic melanoma and prognostic factors for prediction of progression of stage III disease.ResultsIn this feasibility study, several proteins were identified that positively correlated to tumor tissue content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content. Other proteins were inversely correlated to tumor tissue content, the most significant being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of processes involved in progression from stage III to stage IV disease and poor survival.ConclusionIn this feasibility study, promising results show the feasibility of relating proteomics to histopathology and clinical outcome, and insight thus can be gained into the molecular processes driving the disease. The combined analysis of histological features including the sample cellular composition with protein expression of each metastasis enabled the identification of novel, differentially expressed proteins. Further studies are necessary to determine whether these putative biomarkers can be utilized in diagnostics and prognostic prediction of metastatic melanoma.

show abstract

The proportion cured of patients diagnosed with Stage III–IV cutaneous malignant melanoma in Sweden 1990–2007: A population‐based study

Cited by 8 publications

References 37 publications

Prognostic risk factors of first recurrence in patients with primary stages I–II cutaneous malignant melanoma – from the population‐based Swedish melanoma register

Prognostic risk factors of first recurrence in patients with primary stages I–II cutaneous malignant melanoma – from the population‐based Swedish melanoma register

Long‐term survival after childhood acute lymphoblastic leukaemia: population‐based trends in cure and relapse by clinical characteristics

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

Contact Info

Product

Resources

About